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Abstract 
In Lewis rats, treatment with high doses of cyclosporin A (CsA) suppresses clinical signs of 
experimental autoimmune encephalomyelitis (EAE), although disease occurs when treatment 
is ceased. Treatment with low doses of CsA causes EAE to take a chronic relapsing course. 
We have previously shown that CsA treatment causes a decline in the number of T cells and 
increased inflammatory cell apoptosis in the spinal cord. The present study was undertaken to 
assess whether CsA therapy also modulates cytokine mRNA expression by inflammatory 
cells in the spinal cord of rats with EAE, looking for changes that might contribute to the 
observed effects of CsA on the course of EAE. EAE was induced in Lewis rats by inoculation 
with myelin basic protein and adjuvants. At the peak of neurological signs, on day 14 after 
inoculation, rats were given a single intraperitoneal injection of saline, or CsA at a dose of 8, 
16, 32 or 64 mg/kg. The next day, rats were sacrificed, the spinal cords removed, 
inflammatory cells were extracted from the cords, and mRNA isolated from these cells. 
Expression of cytokine mRNA was assessed by semi-quantitative reverse transcription 
polymerase chain reaction (PCR) and by quantitative real-time PCR. With both techniques, 
we found that CsA suppressed the expression of interferon-  mRNA and interleukin-2 (IL-2) 
mRNA. With real-time PCR, we found that CsA caused significantly increased expression of 
transforming growth factor-  mRNA. With the different techniques, we observed no 
consistent pattern of alteration of expression of interleukin-10 or interleukin-4 mRNA. It is 
possible that these changes in cytokine mRNA expression contribute to the modulation of the 
clinical course of EAE that is produced by CsA treatment.  
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1. Introduction 
Experimental autoimmune encephalomyelitis (EAE) is a CD4+ T cell mediated disease of the 
central nervous system (CNS) that can be induced by inoculation with CNS antigens, such as 
myelin basic protein (MBP), and adjuvants. It is widely studied as an animal model of 
multiple sclerosis. EAE is characterized by the infiltration of the nervous system with 
lymphocytes and macrophages, with subsequent demyelination of nerve fibres. In Lewis rats, 
EAE induced by inoculation with MBP (MBP-EAE) is an acute monophasic illness from 
which rats spontaneously recover. In various models of EAE, it has been shown that cytokines 
are involved in the pathogenesis and regulation of disease. Interleukin 2 (IL-2) is present in 
the CNS in EAE 1 2 3 4 . Although interferon-  (IFN- ) is produced by encephalitogenic T 
cells, and thus may be involved in the pathogenesis of EAE, it may also play an 
immunoregulatory role in EAE 5 6 7 8. IL-4 has been found in the CNS in EAE in rats and mice 
9 10. Expression of IL-10 mRNA in the CNS correlates with clinical recovery from EAE in 
mice 10 and cells producing IL-10 mRNA are present in the CNS of rats during recovery from 
EAE 11. Transforming growth factor (TGF)-  mRNA is expressed strongly in the CNS and 
may play a role in the recovery from MBP-EAE in Lewis rats 9 12. Using semi-quantitative 
reverse transcription PCR (RT-PCR), we have previously shown that mRNA of the pro-
inflammatory cytokines (IL-2 and IFN- ) and anti-inflammatory cytokines (IL-4 and IL-10) 
are expressed in the spinal cord during the course of acute MBP-EAE in the Lewis rat 13.  
Cyclosporin A (CsA), described by Borel et al. 14 in 1976, is a cyclic peptide with 
immunomodulatory properties. CsA acts within the cell by binding to cyclophilin, which 
results in the inactivation of calcineurin, and subsequent suppression of transcription of genes, 
including those for cytokines and cytokine receptors 15 16. Treatment with CsA in high doses 
has been shown to suppress clinical signs of EAE in different species 17, including Lewis rats 
18 19. Cyclopsorin A also has a modest beneficial effect on the progression of disability in 
progressive multiple sclerosis 20. Treatment with low doses of CsA (4–8 mg/kg) converts 
acute EAE, induced in Lewis rats by inoculation with spinal cord or with myelin basic 
protein, into a chronic relapsing form of disease 18 19 21. There are other examples of the 
exacerbation of autoimmunity after CsA treatment—namely, the development of graft versus 
host disease after bone marrow transplantation 22 and development of autoimmunity after 
neonatal treatment with CsA 23.  
The suppression of clinical signs of EAE by treatment with high doses of CsA is likely to be 
due to the immunosuppressive effects of CsA, which include suppression of early events in T 
cell activation 24 and suppression of antigen presentation by macrophages 25. These effects 
could occur in the CNS or in the periphery and lead to downregulation of disease in the CNS. 
We have shown that a single treatment with high dose CsA causes a significant reduction in 
the number of T cells in the spinal cord of rats with EAE, and an increase in the number of 
apoptotic lymphocytes in the spinal cord 19. CsA also inhibits the disruption of the blood–
brain barrier that occurs in EAE 26. We have previously suggested that the production of 
relapsing disease after treatment with lower doses of CsA is likely to be due to the modulation 
of mechanisms that regulate the course of disease 19 27 28. Such mechanisms include apoptosis 
of T cells in the CNS 29 30 31 32 33 and production of regulatory cytokines in the CNS 13. We 
have studied the chronic relapsing forms of EAE induced by CsA therapy and shown that 
these are characterized by recurrent episodes of inflammation and demyelination of the 
nervous system 21 28.  
Our previous studies of the effects of CsA on EAE have indicated that CsA therapy can 
modulate the numbers of cells in the inflammatory infiltrate. The present study was carried 
out to determine whether CsA treatment also alters cytokine mRNA expression by 
inflammatory cells in the CNS of rats with MBP-EAE. For simplicity, we chose to study the 
effects of a single dose of CsA. To assess the effects of CsA, we used semi-quantitative 
reverse transcription (RT)-PCR, which we have previously used to study cytokine expression 
in this form of EAE 13. We also used quantitative real-time PCR, which is a new technique 
that has not previously been used to measure cytokine mRNA expression in EAE.  
2. Materials and methods 
2.1. Induction of EAE and CsA treatment 
MBP was prepared from guinea pig brains by the method of Deibler et al. 34. MBP in 0.9% 
saline was emulsified in an equal volume of incomplete Freund's adjuvant containing 4 mg/ml 
Mycobacterium butyricum. On day 0, anaesthetized rats were inoculated in one hind footpad 
with 0.1 ml emulsion containing 50 g MBP per rat. Rats were weighed on day 0 and daily 
from day 8. We assessed the weakness of the tail, hindlimbs and forelimbs. The degree of 
weakness of each region was separately graded on a scale of 0 (no weakness) to 4 (total 
paralysis) as previously described 35. The scores from each region were added together to give 
a total clinical score (maximum total clinical SCORE=12). CsA or saline was administered by 
intraperitoneal injection on day 14, 16 h before study on day 15. Rats were treated with saline 
or CsA in groups of two or three. The spinal cords of all rats in the group were pooled for 
PCR studies.  
2.2. Extraction of cells from the spinal cord and extraction of mRNA 
As described previously 33, cells were isolated from the spinal cords of anaesthetized rats 
perfused with ice-cold saline. The entire spinal cords were removed by insufflation, weighed, 
and a single-cell suspension in ice-cold RPMI 1640 containing 1% foetal calf serum (FCS) 
was prepared by passage through a 200-size mesh stainless steel sieve. The cell suspension 
was mixed with isotonic Percoll (Percoll: Hank's balanced salt solution 9:1) in a 3:2 ratio 
(density 1.052) in 50 ml centrifuge tubes and centrifuged for 25 min at 640×g at 4°C. The 
myelin layer and supernatant were discarded, while the last 9 ml supernatant and the cell 
pellet were retained. The cell pellet and the last 9 ml supernatant were resuspended, 
transferred to a conical 10 ml centrifuge tube, underlaid with 1 ml Ficoll and centrifuged for 
20 min at 600×g at 4°C. Cells were harvested from the interface above the Ficoll, resuspended 
in medium, washed once and counted. In the present study, cells were not passed over nylon 
wool. Messenger RNA was extracted from spinal cord inflammatory cells using Pharmacia 
QuickPrep Micro mRNA Purification Kit (a guanidinium thiocyanate-based extraction 
followed by oligo(dT) purification of mRNA). The mRNA was stored at −20°C before RT-
PCR.  
2.3. Semi-quantitative RT-PCR 
Samples of mRNA (0.05 g) were reverse transcribed using random hexamers as primers and 
MuLV reverse transcriptase under the following conditions: 5 mM MgCl2, 50 mM KCl, 10 
mM Tris–HCl pH 8.3, 1 mM dNTPs, 5 M Random Hexamers (GibCoBRL), 1 U/ l RNase 
Inhibitor (Perkin Elmer), 2.5 U MuLV reverse transcriptase (Perkin Elmer) and 0.05 g 
poly(A+)mRNA in a total volume of 20 l. Samples were incubated at room temperature for 
10 min prior to reverse transcription. The reagents were overlaid with mineral oil and the 
reactions carried out in thin-walled tubes in a Perkin Elmer DNA Thermal Cycler (15 min at 
42°C, 5 min at 99°C and 5 min at 5°C). PCR was carried out under the following conditions: 
3.2 mM MgCl2, 10 mM KCl, 62 mM Tris–HCl pH 8.3, 16 mM (NH4)2SO4, 0.008% (w/v) 
Tween, 0.2 mM dNTPs, 0.15 M of each primer and 0.02 U/ l Red Hot Taq DNA 
Polymerase (Integrated Sciences) in a total reaction volume of 100 l (that contained the 
entire 20 l RT products). The reagents were mineral oil-overlaid and the PCR reaction was 
carried out in thin-walled tubes in a Perkin Elmer DNA Thermal Cycler (2 min at 95°C; then 
37 cycles of 1 min at 95°C and 1 min at 60°C 20 cycles for -actin; then 7 min at 72°C). 
Primers with the following sequences were synthesized by the Queensland Institute of 
Medical Research: 
 
The primer sequences for IL-2, IL-10 and IFN-  were those used by Weinberg et al. 36 in a 
study of MBP-EAE in the rat. The primers for IL-4 and -actin were those used by McKnight 
et al. 37. The sequences of rat -actin 38, IL-2 39 (Genbank M22899), IL-4 37 (Genbank 
X16058), IL-10 40 (Genbank X60675) and IFN-  41 (Genbank X0237, X0236, X0235) are 
known. The sequences used in the present study are specific for the known rat sequences, 
except for those indicated with asterisks, which are specific for mouse sequences and differ 
from the rat sequences by the number of base pairs shown in brackets. The predicted product 
sizes are: -actin, 607 bp; IL-2, 449 bp; IL-4, 378 bp; IL-10, 201 bp; IFN- , 383 bp. The 
sequences chosen all crossed exon boundaries. We have previously shown that the products of 
these primers are labelled by probes specific for the cytokine sequences 13.  
2.4. Real-time PCR 
Real-time PCR using the ABI Prism 7700 Sequence Detection system (Perkin Elmer) was 
used to quantify cytokine expression. Primers and fluorogenic probes with the following 
sequences were custom designed using the ABI Prism Primer Express software (PE 
Biosystems), using the sequences of rat IL-2 39, rat IL-10 40, IFN-  41 42 and rat TGF-  43. 
 
The primers and probes for GAPDH were purchased as predesigned endogenous control kit 
(PE Biosystems). The sequences are therefore not available.  
Reverse transcription and PCR were performed in a single-step procedure using a Gold RT-
PCR (one step) Kit (PE Biosystems). To allow fluorochrome detection, specifically designed 
optical tubes contained in a 96-well microtitre plate (PE Applied Biosystems) were used. 
Samples were tested in duplicate, with and without reverse transcriptase, and the results for 
the sample without reverse transcriptase were subtracted from the results of the sample with 
reverse transcriptase, to allow detection of DNA contamination. The method followed the 
manufacturer's instructions under the following conditions: 5.5 mM MgCl2, 1×TaqMan 
Buffer, 300 M dNTPs, 0.4 U/ l RNAase Inhibitor, 0.25 U/ l Multiscribe Reverse 
Transcriptase, 0.025 U/ l AmpliTaq Gold DNA polymerase, 200 nM forward and reverse 
primers, 100 nM TaqMan probe and 0.05 g of poly(A+)mRNA in a total volume of 50 l. 
Tubes were sealed with optical caps, and a one-step RT-PCR was performed as follows: 30 
min at 40°C, 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 95°C.  
Cytokine expression data obtained from the real-time PCR studies were analyzed 
quantitatively using a comparative CT method. For each cytokine, the threshold, or cycle 
number, at which product was detected, was compared to an endogenous (GAPDH) and 
exogenous control (saline-treated group). Prior to commencing studies, the comparative CT 
method was validated by ensuring that the efficiencies of both the target cytokine and 
GAPDH primers were approximately equal. Results in the first instance were calculated as 
∆CT, i.e. the difference between the cytokine and GAPDH mean thresholds. A ∆∆CT was then 
determined by deducting the mean ∆CT saline result from the mean ∆CT result of each of the 
CsA treatment groups. Normalizing the thresholds of treatment groups to those of saline 
ensured that the standard deviations of the ∆CT and the ∆∆CT were the same. Results were 
finally expressed as 2−∆∆CT which is an index of the amount of cytokine expressed in the 
spinal cord. These results were also expressed as cytokine expression per gram of spinal cord 
by multiplying the results by the number of cells/g of spinal cord.  
 
2.5. Statistical methods 
 
Results from different groups were compared using analysis of variance (ANOVA) with post-
hoc comparison of means of single groups using Sigmastat (Jandel Scientific).  
 
3. Results 
 
3.1. Clinical details 
 
Table 1 shows the clinical details of rats used in the study. Rats in the different groups did not 
differ significantly in the mean day of onset of disease or the clinical score on the day of 
injection (day 14). Table 1 also indicates that, although treatment with high dose CsA on 
alternate days can suppress clinical signs of MBP-EAE 19, treatment with a single injection of 
CsA did not alter the clinical course of disease.  
 
 Table 1. Clinical details of rats used in the study  
3.2. Effect of CsA on number of cells per gram of spinal cord 
The effect of CsA on the total number of cells obtained per gram of spinal cord, for all rats in 
the study, is shown in Fig. 1. It can be seen that a single dose of CsA caused a dose-dependent 
reduction in the number of inflammatory cells/g of spinal cord, with significant declines at 
doses of 16 and 64 mg/kg. Using this technique, we have previously shown that these cells 
extracted from the spinal cord of rats with MBP-EAE are predominantly T lymphocytes and 
macrophages/microglia 33 and that CsA causes a decline in the number of T cells in the spinal 
cord 19.  
 
Fig. 1. Mean (SD) number of inflammatory cells/g of spinal cord, for saline-treated rats and rats treated 
with CsA. The results from rats in the semi-quantitative RT-PCR study and in the real-time PCR study 
are combined. CsA caused a decline in the number of inflammatory cells/g of spinal cord. (Kruskal–
Wallis ANOVA on ranks, p=0.001). Post-test calculations (Dunn's method) showed that the means 
represented by * differed significantly (p<0.05) from the mean for saline-treated rats.  
3.3. Semi-quantitative RT-PCR 
The results of cytokine expression, normalized to -actin, are shown in Fig. 2A. Because CsA 
therapy causes a reduction in the total number of cells in the spinal cord, the expression of 
cytokine per gram of spinal cord is shown in Fig. 2B. As we have previously shown with 
untreated rats with MBP-EAE 13, in the saline-treated rats there was an expression of all 
cytokines. Treatment with CsA significantly suppressed the expression of IL-2 and IFN-  
mRNA, both normalized to -actin and when expressed as cytokine/g. There was no 
significant alteration of expression of IL-4 mRNA. With this technique, there was an apparent 
reduction in the expression of IL-10 mRNA, but this was significant only when expressed as 
cytokine/g.  
 Fig. 2. (A) Results of semi-quantitative RT-PCR showing mean (SEM) cytokine expression normalized 
to -actin. CsA treatment was administered to rats with MBP-EAE as a single intraperitoneal injection 
on day 14, 16 h before sacrifice on day 15. Inflammatory cells were extracted from the spinal cord, and 
mRNA was extracted from the cells. Semi-quantitative RT-PCR was performed and the results are 
expressed as a ratio of cytokine expression to -actin expression. Groups were compared using 
ANOVA. Post-test calculations (Dunn's method) showed that the means represented by * differed 
significantly (p<0.05) from the mean for saline-treated rats. CsA therapy caused a significant 
suppression of expression of IL-2 and IFN- . (B) Results of semi-quantitative RT-PCR showing mean 
(SEM) cytokine expression per gram of spinal cord. Groups were compared using ANOVA. Post-test 
calculations (Dunn's method) showed that the means represented by * differed significantly (p<0.05) 
from the mean for saline-treated rats. CsA therapy caused a significant suppression of expression of IL-
2 and IFN- .  
3.4. Quantitative real-time PCR 
The results of real-time PCR are shown in Table 2. The threshold cycle (CT) for GAPDH was 
constant in all groups and was not influenced by CsA therapy. The results of cytokine 
expression after CsA are given as mean ∆CT. In the saline-treated rats, there was an 
expression of all cytokines. In the CsA-treated rats, there was a significant increase in the ∆CT 
for IFN-  and a significant decrease in the ∆CT for TGF- , compared to the saline-treated 
rats. CsA treatment caused an increase in the ∆CT for IL-2, in a dose-dependent manner, but 
this was not statistically significant. There was no significant change in the ∆CT for IL-10 or 
IL-4.  
 
 
Table 2. Results of real-time PCR  
The amount of mRNA in the starting sample can be calculated as 2−∆∆CT. Fig. 3 illustrates the 
results of these calculations showing the amount of each cytokine expressed as 2−∆∆CT. This 
reflects the expression of cytokine mRNA in equivalent amounts of total inflammatory cell 
mRNA, but is not adjusted for the numbers of cells present in the spinal cord. There was a 
decline in the amount of IL-2 and IFN-  mRNA, but this was not statistically significant. 
There was a highly significant increase in the amount of TGF-  mRNA. There was a slight 
decline in the expression of IL-4 mRNA but this was not statistically significant.  
 
Fig. 3. Results of real-time PCR showing mean cytokine mRNA expression, relative to saline. CsA 
treatment was administered to rats with MBP-EAE as a single intraperitoneal injection on day 14, 16 h 
before sacrifice on day 15. Inflammatory cells were extracted from the spinal cord, and mRNA was 
extracted from the cells. Real-time PCR was performed and the results are expressed as 2−∆∆CT, which 
gives an indication of cytokine expression normalized to GAPDH and then normalized to the 
expression of cytokine in the saline-treated rats. Groups were compared using ANOVA. Post-test 
calculations (Dunn's method) showed that the means represented by * differed significantly (p<0.05) 
from the mean for saline-treated rats. CsA therapy caused dose-dependent suppression of expression of 
IL-2 and IFN-  mRNA, and an increase in expression of TGF-  mRNA, but these results were 
statistically significant only for TGF- .  
Because CsA therapy causes a decline in the number of inflammatory cells obtained per gram 
of spinal cord, we also calculated the expression of cytokine mRNA per gram of spinal cord 
(Fig. 4). This result best expresses the amount of mRNA present in the spinal cord after 
treatment. There was a significant decline in the amount of IL-2 and IFN-  mRNA per gram 
of spinal cord and a significant increase in the expression of TGF-  mRNA, although not at 
all doses. There was a decline in the expression of IL-4 mRNA, but this was not significant. 
There was no change in the IL-10 mRNA expression.  
 
Fig. 4. Results of real-time PCR showing mean cytokine mRNA expression per gram of spinal cord, 
relative to saline. Real-time PCR was performed as in Fig. 3 and the results have been adjusted for the 
number of cells/g of spinal cord. Groups were compared using ANOVA. Post-test calculations (Dunn's 
method) showed that the means represented by * differed significantly (p<0.05) from the mean for 
saline-treated rats. CsA therapy caused a significant dose-dependent suppression of expression of IL-2 
and IFN-  mRNA, and an increase in expression of TGF-  mRNA.  
4. Discussion 
In this study, we used PCR to study the effects of a single injection of CsA on cytokine 
mRNA expression by inflammatory cells from the CNS of rats with MBP-EAE. The cells 
extracted from the spinal cord comprise T lymphocytes and macrophages/microglia 19 44 45. 
We have previously shown that therapy with high dose CsA suppresses MBP-EAE, although 
rats have an episode of disease after therapy is ceased, and that low dose CsA causes chronic 
relapsing EAE 19. We have also demonstrated that a single dose of CsA leads to a reduction in 
the number and percentage of T cells, as well as increased T cell apoptosis, and an increase in 
the percentage of macrophages/microglia in the inflammatory infiltrate in the spinal cord in 
rats with EAE 19. The present study confirmed that a single dose of CsA causes a reduction in 
the number of inflammatory cells obtained from the spinal cord. Two PCR techniques were 
used, which gave similar results. Initially, a semi-quantitative RT-PCR was employed, 
extending previous studies by this laboratory which have demonstrated expression of IL-2, 
IL-4, IL-10 and IFN-  mRNA in CNS inflammatory cells throughout the course of MBP-
EAE in Lewis rats 13. We also used quantitative real-time PCR, a new technique that has not 
previously been used in studies of EAE. All cytokine mRNAs were detected with both 
methods, with the exception of TGF- , which was not studied with the initial semi-
quantitative experiments. Cytokine mRNA expression in the saline-treated control group was 
found to be similar to that previously found in untreated rats with MBP-EAE 13. Some 
variability was noted in the results obtained with real-time PCR, due in part to fluctuations in 
the individual CT values for GAPDH. This was not attributed to an effect of CsA treatment as 
no dose-dependent changes in the mean CT for GAPDH were observed. It has been suggested 
that GAPDH may vary in expression and ribosomal RNA may be a better internal standard 
than GAPDH for future studies 46.  
With both techniques, CsA therapy suppressed expression of IFN-  mRNA in inflammatory 
cells from the spinal cords of rats with MBP-EAE. There was also a dose-dependent reduction 
in expression of IL-2 mRNA. Real-time PCR showed a significant increase in the expression 
of TGF-  mRNA although this was not dose-dependent. There was some variability in the 
results of expression of IL-10 and IL-4 mRNA with the two techniques, and no consistent 
finding was demonstrated. As the experiments were performed on whole animals, these 
observations represent the final effect of CsA treatment on the expression of cytokine mRNA 
in the CNS in MBP-EAE. However, the results do not necessarily represent direct effects of 
CsA on cytokine expression in the CNS, as the alteration in the expression of cytokine mRNA 
may have occurred before the cells entered the CNS. We have previously shown that CsA 
treatment of MBP-EAE causes a decline in the proportion of T cells in the spinal cord 
inflammatory infiltrate 19. Such a decline could also contribute to a decrease in the expression 
of T cell cytokine mRNA in the inflammatory infiltrate. However, the present study was 
performed to measure the overall effect of CsA on total cytokine mRNA expression in the 
spinal cord rather than to measure the expression by specific cells.  
Our observations are in keeping with the known effects of CsA. In vitro, CsA inhibits early 
events in T cell activation and suppresses IL-2 and IFN-  expression in response to mitogen 
stimulation of T cells 47 48. TGF-  expression by epithelial cells in vitro is enhanced by CsA 49 
50. In our study, with the different PCR techniques, we did not find consistent changes in IL-
10 mRNA or IL-4 mRNA expression. It has been found that CsA suppresses IL-4 expression 
but has no effect on the IL-10 expression in mitogen-stimulated cells in vitro 51. However, in a 
study of cytokine expression in transplanted hearts in Wistar rats, CsA treatment for 7 days 
did not inhibit the expression of IL-4 but did inhibit IL-10 expression 52.  
The modulation of cytokine expression that we observed in the present study may contribute 
to the ability of CsA therapy to modulate the course of EAE 19. The significant increase in the 
expression of TGF-  mRNA by inflammatory cells in the CNS is likely to have a down-
regulatory role as numerous studies have revealed that TGF-  production correlates with the 
resolution of inflammatory responses, particularly in organ-specific autoimmune diseases 53. 
TGF-  has a wide range of immunosuppressive effects 54 and is thought to downregulate 
EAE 9 12, so the increased expression of TGF-  would be expected to be associated with the 
suppression of disease. IL-2 and IFN-  are secreted by encephalitogenic cells, and reduction 
in the expression of these cytokines would be expected to accompany a reduction in the 
inflammatory infiltrate. However, although IFN-  is involved in the pathogenesis of EAE, it 
may also play a role in immunoregulation 5 6 7 8. Reduction in IFN-  expression after 
treatment with CsA could therefore potentially enhance disease. Tanuma et al. 55 have 
suggested that the suppression of IFN-  by CsA may be involved in the induction of chronic 
relapsing EAE by CsA. They compared the first episode of CsA-induced chronic relapsing 
EAE with the second episode and found that IFN-  expression by inflammatory cells in the 
CNS is impaired in the first compared to the second episode. In summary, we have shown that 
CsA therapy modulates the expression of cytokine mRNA in the CNS in MBP-EAE and 
suggest that these changes may contribute to the observed clinical effects of CsA on EAE.  
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